Cargando…

Formulation and Evaluation of Cephalexin Extended Release Matrix Tablets Using 3(2) Factorial Design

The aim of the present investigation was to prepare extended release film coated matrix tablets of cephalexin using binary mixture of two grades of hydrophilic polymer, hydroxypropyl methyl cellulose (HPMC), by direct compression method. Results of the preliminary trials indicated that the polymers...

Descripción completa

Detalles Bibliográficos
Autores principales: Jishnu, V, Prabhakaran, R, Gilhotra, RM
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249737/
https://www.ncbi.nlm.nih.gov/pubmed/22224031
http://dx.doi.org/10.4103/0975-1483.90233
_version_ 1782220375388585984
author Jishnu, V
Prabhakaran, R
Gilhotra, RM
author_facet Jishnu, V
Prabhakaran, R
Gilhotra, RM
author_sort Jishnu, V
collection PubMed
description The aim of the present investigation was to prepare extended release film coated matrix tablets of cephalexin using binary mixture of two grades of hydrophilic polymer, hydroxypropyl methyl cellulose (HPMC), by direct compression method. Results of the preliminary trials indicated that the polymers used have significant release retarding effect on the formulation. To study the effect of concentration of polymers on drug release from matrix tablets, 3(2) full factorial design was applied. The concentration of HPMC K15M and HPMC 15cps were used as independent variables, while percentage drug release was selected as dependent variable. The dissolution data were fitted into zero-order, first-order, Higuchi and Korsemeyer–Peppas models to identify the pharmacokinetics and mechanism of drug release. Comparative study of dissolution profile of final batch F3 with market preparation (Sporidex AF 375) was done by similarity factor (f(2)) determination and it was concluded that final formulation F3 (10% HPMC K15M, 17.5% HPMC 15cps) shows good similarity with the market product. The results of the accelerated stability study of final formulation F3 for 1 month revealed that storage conditions were not found to have made any significant changes in final formulation F3. The release of cephalexin was prolonged for 6 h by using polymer combinations of HPMC and a twice daily matrix tablet was formulated.
format Online
Article
Text
id pubmed-3249737
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-32497372012-01-05 Formulation and Evaluation of Cephalexin Extended Release Matrix Tablets Using 3(2) Factorial Design Jishnu, V Prabhakaran, R Gilhotra, RM J Young Pharm Pharmaceutics The aim of the present investigation was to prepare extended release film coated matrix tablets of cephalexin using binary mixture of two grades of hydrophilic polymer, hydroxypropyl methyl cellulose (HPMC), by direct compression method. Results of the preliminary trials indicated that the polymers used have significant release retarding effect on the formulation. To study the effect of concentration of polymers on drug release from matrix tablets, 3(2) full factorial design was applied. The concentration of HPMC K15M and HPMC 15cps were used as independent variables, while percentage drug release was selected as dependent variable. The dissolution data were fitted into zero-order, first-order, Higuchi and Korsemeyer–Peppas models to identify the pharmacokinetics and mechanism of drug release. Comparative study of dissolution profile of final batch F3 with market preparation (Sporidex AF 375) was done by similarity factor (f(2)) determination and it was concluded that final formulation F3 (10% HPMC K15M, 17.5% HPMC 15cps) shows good similarity with the market product. The results of the accelerated stability study of final formulation F3 for 1 month revealed that storage conditions were not found to have made any significant changes in final formulation F3. The release of cephalexin was prolonged for 6 h by using polymer combinations of HPMC and a twice daily matrix tablet was formulated. Medknow Publications & Media Pvt Ltd 2011 /pmc/articles/PMC3249737/ /pubmed/22224031 http://dx.doi.org/10.4103/0975-1483.90233 Text en Copyright: © Journal of Young Pharmacists http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Pharmaceutics
Jishnu, V
Prabhakaran, R
Gilhotra, RM
Formulation and Evaluation of Cephalexin Extended Release Matrix Tablets Using 3(2) Factorial Design
title Formulation and Evaluation of Cephalexin Extended Release Matrix Tablets Using 3(2) Factorial Design
title_full Formulation and Evaluation of Cephalexin Extended Release Matrix Tablets Using 3(2) Factorial Design
title_fullStr Formulation and Evaluation of Cephalexin Extended Release Matrix Tablets Using 3(2) Factorial Design
title_full_unstemmed Formulation and Evaluation of Cephalexin Extended Release Matrix Tablets Using 3(2) Factorial Design
title_short Formulation and Evaluation of Cephalexin Extended Release Matrix Tablets Using 3(2) Factorial Design
title_sort formulation and evaluation of cephalexin extended release matrix tablets using 3(2) factorial design
topic Pharmaceutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249737/
https://www.ncbi.nlm.nih.gov/pubmed/22224031
http://dx.doi.org/10.4103/0975-1483.90233
work_keys_str_mv AT jishnuv formulationandevaluationofcephalexinextendedreleasematrixtabletsusing32factorialdesign
AT prabhakaranr formulationandevaluationofcephalexinextendedreleasematrixtabletsusing32factorialdesign
AT gilhotrarm formulationandevaluationofcephalexinextendedreleasematrixtabletsusing32factorialdesign